Description: Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Home Page: verupharma.com
2916 North Miami Avenue
Miami,
FL
33127
United States
Phone:
305 509 6897
Officers
| Name | Title |
|---|---|
| Dr. Mitchell S. Steiner F.A.C.S., M.D. | Chairman, President & CEO |
| Dr. Harry Fisch F.A.C.S., M.D. | Vice Chairman & Chief Corporate Officer |
| Ms. Michele Greco CPA | CFO & Chief Administrative Officer |
| Dr. K. Gary Barnette Ph.D. | Chief Scientific Officer |
| Mr. Samuel Fisch | Executive Director of Investor Relations & Corporate Communications |
| Mr. Michael J. Purvis J.D. | Executive VP, General Counsel & Corporate Strategy and Secretary |
| Mr. Kevin J. Gilbert CPA, J.D. | Executive Vice President of Corporate Development |
| Mr. Martin Tayler | Executive Vice President of FC2 Global Operations |
| Mr. Philip R. Greenberg J.D. | Executive VP & Deputy General Counsel |
| Dr. Domingo Rodriguez M.D. | Executive Vice President of Global Clinical Operations |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.7637 |
| Price-to-Sales TTM: | 7.1149 |
| IPO Date: | |
| Fiscal Year End: | September |
| Full Time Employees: | 189 |